At Home Gamma tACS in Alzheimer's Disease (tACS@Home)

Launched by AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA · Dec 7, 2022

Keywords

ClinConnect Summary

The clinical trial titled "At Home Gamma tACS in Alzheimer's Disease" is studying a new way to help improve symptoms in patients with mild Alzheimer's disease. The researchers are looking at a treatment called transcranial alternating current stimulation (tACS), which is a non-invasive method that uses gentle electrical currents to stimulate the brain. This treatment aims to restore brain activity patterns that are often disrupted in Alzheimer’s, potentially leading to better cognitive function and memory. Participants will receive either the active treatment or a sham (placebo) treatment over a period of 9 to 18 weeks, all while being able to do it from home.

To be eligible for this trial, participants must have mild Alzheimer's disease, specifically classified as having mild cognitive impairment (with a score of 0.5 to 1 on the Clinical Dementia Rating scale). They will not be able to join if they have certain medical conditions, like a history of strokes or other serious brain injuries. Caregivers aged 18 and older are also included in the study to help with the training on using the device. Overall, this trial aims to gather important information about how this innovative treatment might help those living with Alzheimer's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for the Patient:
• • Mild Alzheimer's disease (CDR 0.5 - 1)
• Exclusion Criteria for the Patient:
• • Cerebrovascular disorders
• • Previous stroke
• • Hydrocephalus
• • Intra-cranial mass documented by MRI
• • History of traumatic brain injury or other neurological diseases
• • Serious medical illness other than AD
• • History of seizures
• • Pregnancy
• • Metal implants in the head (except dental fillings)
• • Electronic implants (i.e. pace-maker, implanted medical pump)
• • Age \<18 years
• Inclusion Criteria for the Caregiver:
• • Age \> 18 years
• • Compliance in participation in training on the use of the therapeutic device
• • Mini-Mental State Examination \>26/30

Trial Officials